

Securities and Exchange Commissions,
Division of Corporate Finance,
450 Fifth Street,
Washington, D.C. 20549
USA



SUPPL



30/03/2005

Re.: SEC File Number, 82-5116

This information is furnished pursuant to Rule 12g3-2(b).

Kindly receive press releases nos. 13-21 (incl.) sent to the Copenhagen Stock Exchange in March, 2005.

Yours sincerely
Novozymes A/S


Ella Begtrup
Investor Relations
+45 44 42 23 79

PROCESSED
APR 07 2005 E
THOMSON
FINANCIAL



Stock exchange announcement

March 29, 2005

Novozymes A/S

Summary and key figures for the Novozymes Group for 2004 in accordance with IFRS

Novozymes changed its accounting policies with effect from January 1, 2005 and will henceforth follow the International Financial Reporting Standards (IFRS). In order to provide a basis of comparison for future financial statements, the key figures for the full year and the individual quarters of 2004 are restated here in accordance with the principles of the IFRS.

Profit/loss and balance sheet - IFRS

(DKK million)	Before IFRS 2004	IFRS effect	After IFRS 2004	2004 - IFRS			
				Q4	Q3	Q2	Q1
Net turnover	6,024	(36)	5,988	1,491	1,536	1,528	1,433
- Enzymes	5,726	(36)	5,690	1,424	1,469	1,445	1,352
- Microorganisms	298	0	298	67	67	83	81
Gross profit	3,179	(29)	3,150	743	815	817	775
- Enzymes	3,017	(29)	2,988	704	781	772	731
- Microorganisms	162	0	162	39	34	45	44
Operating profit (EBIT)	1,090	(1)	1,089	252	317	261	259
- Enzymes	1,057	(9)	1,048	239	313	249	247
- Microorganisms	33	8	41	13	4	12	12
Operating profit margin	18.1%		18.2%	16.9%	20.6%	17.1%	18.1%
Net financials	(9)	(24)	(33)	23	(6)	(33)	(17)
Profit before tax	1,081	(25)	1,056	275	311	228	242
Tax	288	(7)	281	80	80	58	63
Minority interests	(11)	0	(11)	(12)	0	0	1
Net profit	782	(18)	764	183	231	170	180
Earnings per DKK 10 share	11.2		10.9	2.7	3.3	2.4	2.5
Average no. of A/B shares, diluted (million)	69.8		69.8	68.7	69.6	70.3	70.7
Free cash flow	1,080	0	1,080	300	303	103	374
Return on invested capital	17.3%		17.4%				
Shareholders' equity	3,860	57	3,917	3,917	4,051	4,047	3,926
Total assets	7,134	(58)	7,076	7,076	7,563	7,530	7,460

The annual accounts for 2004 have been prepared in accordance with the Danish Company Accounts Act, current Danish accounting standards and the regulations of the Copenhagen Stock Exchange on the presentation of accounts by listed companies. The annual accounts have been audited. The

adjustments resulting from the transition to IFRS, cf. Note 32 in the Novozymes Report 2004, Accounts and Data, have also been audited. The allocation of the effects of the IFRS adjustments on the individual profit/loss and balance sheet items has not been audited.

The adjustments relating to the principal items 'Operating profit', 'Net profit' and the Balance sheet are shown in greater detail in Appendix 1, while the Profit and loss account, Balance sheet and Cash flow and financial resources stated in accordance with the principles of IFRS are shown in Appendix 2.

Reference is also made to Note 32, Transition to IFRS, in the Novozymes Report 2004, Accounts and Data.

Sales by industry

(DKK million)	Before IFRS 2004	IFRS effect	After IFRS 2004	2004 - IFRS			
				Q4	Q3	Q2	Q1
Enzymes	5,726	(36)	5,690	1,424	1,469	1,445	1,352
-technical enzymes	3,553	0	3,553	862	931	897	863
-detergent	2,038	0	2,038	483	525	512	518
-other technical	1,515	0	1,515	379	406	385	345
-food enzymes	1,439	0	1,439	371	373	367	328
-feed enzymes	734	(36)	698	191	165	181	161
Microorganisms	298	0	298	67	67	83	81
Net turnover	6,024	(36)	5,988	1,491	1,536	1,528	1,433

As the table above shows, the change in net turnover only concerns the feed enzymes industry and relates to reclassification concerning the recognition of sub-elements of major cooperation agreements. The reclassification has no effect on operating profit.

Sales by geographical area

(DKK million)	Before IFRS 2004	IFRS effect	After IFRS 2004	2004 - IFRS			
				Q4	Q3	Q2	Q1
Europe, Middle East & Africa	2,679	(18)	2,661	685	691	659	626
North America	1,768	(6)	1,762	400	450	470	442
Asia Pacific	1,116	(6)	1,110	287	280	277	266
Latin America	461	(6)	455	119	115	122	99
Net turnover	6,024	(36)	5,988	1,491	1,536	1,528	1,433

Net financials

(DKK million)	Before IFRS 2004	IFRS effect	After IFRS 2004	2004 - IFRS			
				Q4	Q3	Q2	Q1
Net foreign exchange gain/(loss)	33	0	33	14	10	(1)	10
Net interest expenses	(35)	0	(35)	(10)	(9)	(9)	(7)
Other financials	(7)	(24)	(31)	19	(7)	(23)	(20)
Total financials	(9)	(24)	(33)	23	(6)	(33)	(17)
Net interest-bearing debt, end	706	(42)	664	664	743	841	801

Cash flow, investments, acquisitions

(DKK million)	Before IFRS 2004	IFRS effect	After IFRS 2004	2004 - IFRS			
				Q4	Q3	Q2	Q1
Cash flow before change in working	1,306	0	1,306	369	374	396	167
Cash flow from operating activities	1,287	0	1,287	434	379	171	303
Cash flow from investing activities	(207)	0	(207)	(134)	(76)	(68)	71
Free cash flow	1,080	0	1,080	300	303	103	374
Cash flow from financing activities	(1,029)	0	(1,029)	(306)	(182)	(162)	(379)
Net cash flow	51	0	51	(6)	121	(59)	(5)
Acquisitions	0	0	0	0	0	0	0

Balance sheet and development in shareholders' equity

Assets (DKK million)	Before	End 2004	
		IFRS effect	After
Intangible fixed assets	471	9	480
Tangible fixed assets	3,522	(120)	3,402
Financial fixed assets	0	26	26
Total fixed assets	3,993	(85)	3,908
Stocks	1,130		1,130
Debtors	1,387	(26)	1,361
Securities	93	53	146
Cash at bank and in hand	531		531
Total current assets	3,141	27	3,168
Total assets end 2004	7,134	(58)	7,076

Liabilities (DKK million)	Before	End 2004	
		IFRS effect	After
Shareholders' equity beginning of 2004	4,144		4,144
Retained earnings	782	(18)	764
Dividend paid	(217)		(217)
Purchase of own shares, net	(804)		(804)
Currency translation adj. for net assets, etc.	(45)	75	30
Shareholders' equity end 2004	3,860	57	3,917
Minority interests	32	(2)	30
Total provisions	752	(190)	562
Total long-term liabilities	1,267	0	1,267
Total current liabilities	1,223	77	1,300
Total liabilities	2,490	77	2,567
Total liabilities and shareholders' equity end 2004	7,134	(58)	7,076

The adjustments to the Balance sheet in accordance with IFRS for the individual quarters of 2004 are detailed in Appendix 1.

Appendix 1 details the effect, by quarter, of adjustments and reclassifications resulting from the transition to IFRS on principal items in the Profit and loss account for 2004

Appendix 2 contains the Profit and loss account, Balance sheet – Assets and Liabilities – and Cash flow and financial resources for 2004 before and after adjustment in line with IFRS

Contact persons:**Press and media:**

Eva Louise Holm Petersen

Tel. (direct): +45 4442 3338

Investor Relations

In Denmark:

Lene Aaboe

Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl

Tel. (direct): +45 4443 3304

In USA:

Thomas Kudsk Larsen

Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Appendix 1

Effect of IFRS (DKK million)	2004			
	Q4	Q3	Q2	Q1
Operating profit				
Operating profit - Danish accounting standards	254	314	265	257
Provisions for employee benefits	(5)	0	0	0
Share-based remuneration with own participating interests - employee costs	(3)	(3)	(10)	(4)
Borrowing costs - depreciation	4	4	3	4
Amortisation of goodwill	2	2	3	2
Operating profit - IFRS	252	317	261	259
Net profit				
Net profit - Danish accounting standards	174	230	185	193
Provisions for employee benefits	(5)	0	0	0
Share-based remunerations with own participating interests - employee costs	(3)	(3)	(10)	(4)
Share-based remunerations with own participating interests - fair value adjustm.	(2)	(0)	(4)	(2)
Other share-based remuneration	18	(2)	(14)	(18)
Borrowing costs - depreciation	4	4	3	4
Amortisation of goodwill	2	2	3	2
Tax relating to the above items	(5)	0	7	5
Net profit - IFRS	183	231	170	180

Appendix 1 – cont'd...

Effect of IFRS (DKK million)	2004			
	Q4	Q3	Q2	Q1
Balance sheet				
Total assets - Danish accounting standards	7,134	7,609	7,584	7,534
Fixed assets - Danish accounting standards	3,993	4,151	4,228	4,285
Borrowing costs - depreciation	(120)	(124)	(128)	(131)
Amortisation of goodwill	9	7	5	2
Deferred taxes	26	23	22	23
Fixed assets - IFRS	3,908	4,057	4,127	4,179
Current assets - Danish accounting standards	3,141	3,458	3,356	3,249
Deferred taxes	(26)	(23)	(22)	(23)
Other share-based remuneration	53	71	69	55
Current assets - IFRS	3,168	3,506	3,403	3,281
Total assets - IFRS	7,076	7,563	7,530	7,460
Total shareholders' equity and liabilities	7,134	7,609	7,584	7,534
Shareholders' equity - Danish accounting standards	3,860	4,003	3,997	3,902
Provisions for employee benefits	(11)	(7)	(7)	(7)
Share-based remuneration with own participating interests	(24)	(21)	(21)	(10)
Other share-based remuneration	(0)	0	0	(0)
Borrowing costs - depreciations	(120)	(124)	(128)	(131)
Amortisation of goodwill	9	7	5	2
Tax relating to above items	201	193	201	170
Minority interests - adjustments	2	0	0	0
Shareholders' equity - IFRS	3,917	4,051	4,047	3,926
Minority interests - Danish accounting standards	32	24	25	27
Minority interests - adjustments	(2)	0	0	0
Minority interests - IFRS	30	24	25	27
Liabilities - Danish accounting standards	3,242	3,582	3,562	3,605
Provisions for employee costs	11	7	7	7
Provisions for deferred tax	(201)	(193)	(201)	(170)
Other share-based remuneration	53	71	69	55
Share-based remuneration with own participating interests	24	21	21	10
Liabilities - IFRS	3,129	3,488	3,458	3,507
Total shareholders' equity and liabilities - IFRS	7,076	7,563	7,530	7,460

Appendix 2

Effect of IFRS (DKK million)			
Profit and Loss account	Before IFRS 2004	IFRS effect	After IFRS 2004
Net turnover	6,024	(36)	5,988
Production costs	2,845	(7)	2,838
Gross profit	3,179	(29)	3,150
Sales and distribution costs	750	(41)	709
Research and development costs	775	5	780
Administrative costs	595	8	603
Licence fees and other operating income, net	31	0	31
Operating profit	1,090	(1)	1,089
Financial income	89	0	89
Financial costs	98	24	122
Profit before tax	1,081	(25)	1,056
Corporate tax	288	(7)	281
Profit including minority interests	793	(18)	775
Equity minority interests	(11)	0	(11)
Net profit	782	(18)	764
Proposed dividend per share	3.50		3.50
Earnings per share	11.45	(0.26)	11.19
Earnings per share, diluted	11.20	(0.26)	10.94

Appendix 2 – cont'd...

Effect of IFRS (DKK million)			
Assets	Before IFRS 2004	IFRS effect	After IFRS 2004
Completed IT development projects	93	0	93
Acquired patents, licences and know-how	263	0	263
Goodwill	95	9	104
IT development projects in progress	20	0	20
Intangible fixed assets	471	9	480
Land and buildings	1,842	(96)	1,746
Production plant and machinery	1,045	(24)	1,021
Other equipment	329	0	329
Tangible fixed assets under construction	306	0	306
Tangible fixed assets	3,522	(120)	3,402
Other securities and participating interests	0	26	26
Financial fixed assets	0	26	26
Total fixed assets	3,993	(85)	3,908
Raw materials and consumables	167	0	167
Work in progress	298	0	298
Finished goods	665	0	665
Total stocks	1,130	0	1,130
Trade debtors	859	0	859
Amounts owed by related parties	56	0	56
Tax receivable	227	0	227
Deferred tax receivable	26	(26)	0
Other debtors	219	0	219
Total debtors	1,387	(26)	1,361
Securities	93	53	146
Cash at bank and in hand	531	0	531
Total current assets	3,141	27	3,168
Total assets	7,134	(58)	7,076

Appendix 2 – cont'd...

Effect of IFRS (DKK million)			
Liabilities and shareholders' equity	Before IFRS 2004	IFRS effect	After IFRS 2004
Share capital	726	0	726
Other comprehensive income	(136)	75	(61)
Own participating interests	(1,316)	0	(1,316)
Retained earnings	4,353	(18)	4,335
Proposed dividend	233	0	233
Total shareholders' equity	3,860	57	3,917
Minority interests	32	(2)	30
Provisions for pensions and similar commitments	15	11	26
Provisions for deferred tax	718	(201)	517
Other provision	19	0	19
Total provisions	752	(190)	562
Credit institutions	1,245	0	1,245
Amounts owed to related parties	22	0	22
Total non-current liabilities	1,267	0	1,267
Credit institutions	48	0	48
Trade creditors	202	0	202
Amounts owed to related parties	68	0	68
Tax payable	81	0	81
Other creditors	824	77	901
Total current liabilities	1,223	77	1,300
Total liabilities	2,490	77	2,567
Total liabilities and shareholders' equity	7,134	(58)	7,076

Appendix 2 – cont'd...

Effect of IFRS (DKK million)			
Cash flow and financial resources	Before IFRS 2004	IFRS effect	After IFRS 2004
Net profit	782	(18)	764
Reversals of items with no effect on cash flow	956	18	974
Corporation tax paid	(437)	0	(437)
Interest received	48	0	48
Interest paid	(43)	0	(43)
Cash flow before change in working capital	1,306	0	1,306
Change in working capital			
(Increase)/decrease in trade debtors and other debtors	(1)	0	(1)
(Increase)/decrease in stocks	(42)	0	(42)
Increase/(decrease) in amounts owed to related parties, net	(2)	0	(2)
Increase/(decrease) in trade creditors and other creditors	26	0	26
Cash flow from operating activities	1,287	0	1,287
Investments:			
Purchase of intangible fixed assets	(54)	0	(54)
Sale of tangible fixed assets	2	0	2
Purchase of tangible fixed assets	(281)	0	(281)
Termination of currency swap	131	0	131
Acquisition of activities	0	0	0
Purchase of minority shares	(5)	0	(5)
Cash flow from investing activities	(207)	0	(207)
Free cash flow	1,080	0	1,080
Financing:			
Non-current loan repayments	(500)	0	(500)
Non-current borrowing	470	0	470
Sale of shares in Novo Nordisk A/S	22	0	22
Purchase of own participating interests, net	(804)	0	(804)
Dividend paid	(217)	0	(217)
Cash flow from financing activities	(1,029)	0	(1,029)
Net cash flow	51	0	51
Unrealised gain/(loss) on currencies and securities included in cash and cash equivalents	(4)	0	(4)
Net change in cash and cash equivalents	47	0	47
Cash and cash equivalents at January 1	436	0	436
Cash and cash equivalents at December 31	483	0	483
Undrawn committed credit facilities	3,000	0	3,000
Financial resources at 31 December	3,483	0	3,483

Stock Exchange Announcement

March 17, 2005

Annual meeting of shareholders of Novozymes A/S

The annual meeting of shareholders of Novozymes A/S was held yesterday. The annual meeting adopted the report on the company's activities over the last financial year.

The annual meeting also approved the following items:

- the audited annual report, including the resolution on discharge of the Executive Management and Board of Directors
- a resolution on application of profits in accordance with the approved accounts (annual report), subject to payment of a dividend of DKK 3.50 per DKK 10 share
- re-election of the current six members of the Board of Directors as elected by the shareholders
- re-election of PricewaterhouseCoopers
- reduction of the company's share capital by withdrawing part of the company's holding of own B shares, with a total nominal value of DKK 30,000,000. Following the reduction, the nominal value of the share capital will be DKK 696,000,000, DKK 107,487,200 of which is A shares and DKK 588,512,800 B shares
- authorisation for the Board of Directors, in the period up to the next annual meeting of shareholders, to allow the company to purchase own shares to a value of up to 10% of the share capital at the share price prevailing on the purchase date, with a deviation of up to 10%, cf. Section 48 of the Danish Companies Act.

Henrik Gürtler, chairman of the Board of Directors, made the following comments in his verbal report:

"2004 was a year in which earnings continued to rise and we enjoyed healthy organic growth. We should be proud of these results, which have been achieved despite the unfavourable exchange rate situation, something which has been - and remains - a big challenge for the business.

Running the business in a socially responsible manner and contributing to sustainable development is part of Novozymes' vision and strategy. One specific element of our work on social responsibility is a project concerning business integrity which is intended to ensure that Novozymes lives up to high ethical standards in how it operates its business worldwide."

Composition of the Board of Directors

The officers and members of the Board of Directors are as follows:

Henrik Gürtler, CEO, Novo A/S (Chairman)

Kurt Anker Nielsen, Director, former CEO, Novo A/S (Vice-Chairman)

Paul Petter Aas, Senior Vice President, Yara International

Arne Hansen, Skilled Worker (employee elected)

Jerker Hartwall, President & CEO, Karlshamns AB

Søren Jepsen, Manager (employee elected)

Ulla Morin, Laboratory Technician (employee elected)

Walther Thygesen, General Manager of Hewlett-Packard Danmark and Senior Vice President of Hewlett-Packard, EMEA

Hans Werdelin, Director, former CEO, Sophus Berendsen

Contact

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Investors:

Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Meidahl
Tel (direct): +45 4443 3304

(USA and Canada)
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement



March 16, 2005

Novozymes A/S

Holding of Novozymes shares by insiders – (Status 1, 2005)

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes hereby reports the following:

	Holding of shares Nos. As per Dec. 10, 2004	Holding of shares Nos. As per March 15, 2005	Market value of the total shareholding DKK As per March 15, 2005
Board of Directors	11,627	11,627	3,232,306
Management	30,519	27,019	7,511,282
All insiders, Total	75,272	71,259	19,810,002

Contact persons:

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Investor Relations

Outside USA and Canada:
Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): +45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement



March 14, 2005

Novozymes A/S Trading by insiders in Novozymes A/S B shares - statement no. 16, 2005

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	March 11, 2005	0	DKK 4,434,200	71,259	DKK 20,095,038

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:

Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement



March 11, 2005

Novozymes A/S Trading by insiders in Novozymes A/S B shares - statement no. 15, 2005

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	March 10, 2005	- 3.500	DKK 983,500	71,259	DKK 20,059,408

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:
Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement no. 17/2005

Novozymes A/S
Investor Relations
Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone:
+45 8824 9999
Fax:
+45 4442 1002

Internet:
www.novozymes.com
CVR number:
10 00 71 27

Page 1 of 1

Stock exchange announcement



March 9, 2005

Novozymes A/S **Trading by insiders in Novozymes A/S B shares - statement** **no. 14, 2005**

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	March 8, 2005	-100	DKK 2,036,670	74,779	DKK 21,125,067

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:
Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement



March 8, 2005

Novozymes A/S Trading by insiders in Novozymes A/S B shares - statement no. 13, 2005

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	March 7, 2005	-100	DKK 68,800	74,879	DKK 21,265,636

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:
Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement no. 15/2005

Novozymes A/S
Investor Relations
Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone:
+45 8824 9999
Fax:
+45 4442 1002

Internet:
www.novozymes.com
CVR number:
10 00 71 27

Page 1 of 1

Stock exchange announcement



March 7, 2005

Novozymes A/S **Trading by insiders in Novozymes A/S B shares - statement** **no. 12, 2005**

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	March 3, 2005	0	DKK 1,057,150	74,979	DKK 20,956,630

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:
Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:
Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.

Stock exchange announcement



March 2, 2005

Novozymes A/S

Trading by insiders in Novozymes A/S B shares - statement no. 11, 2005

In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following:

ISIN	Trading date	Number of shares traded, net	Market value of number of shares traded, net	Total number of shares held by insiders	Market value of shares held by insiders
DK0010272129	February 28, 2005	0	DKK 724,900	74,979	DKK 20,884,162

Contact persons

Press and media:

Eva Louise Holm Petersen
Tel. (direct): +45 4442 3338

Equity analysts and investors:

Outside USA and Canada:

Lene Aaboe
Tel. (direct): +45 4446 0082

Niels Eldrup Meidahl
Tel. (direct): + 45 4443 3304

USA and Canada:

Thomas Kudsk Larsen
Tel. (direct): +1 919 494 3279

Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at www.novozymes.com.